Clinical Trial Update: Semaglutide 2.4mg for Low Responders After Bariatric Surgery [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating semaglutide 2.4 mg for low responders after bariatric surgery.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Morbid Obesity
• Obesity
• Weight Gain

Drugs mentioned

• semaglutide 2.4 mg (semaglutide)

Snippet

Sponsor: Zuyderland Medisch Centrum | Conditions: Obesity, Obesity, Morbid | Phase 4 | Status: NOT_YET_RECRUITING